Clinical & translational oncology

• 

  Año 2024, Vol. 26, Número 7

  • REVIEW ARTICLE

    • Safety profle of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management

      Eva Ciruelos, José Ángel García Sáenz, Joaquín Gavilá Gregori, Miguel Martín Jiménez, César Augusto Rodríguez Sánchez, Álvaro Rodríguez Lescure

      • Resumen

      págs. 1539-1548

      

    • What’s new about the tumor microenvironment of urothelial carcinoma?

      João Queirós Coelho, Maria João Ramos, Ridhi Ranchor, Rita Pichel, Laura Guerra, Hugo Miranda, Joana Simões Pereira, Sérgio Xavier Azevedo, Joana Febra, António Araújo

      • Resumen

      págs. 1549-1560

      

    • Towards stronger tobacco control policies to curb the smoking epidemic in Spain

      Mónica Pérez Ríos, Carla Guerra Tort, Guadalupe García, Julia Rey Brandariz, Nerea Mourino, Ana Teijeiro, Raquel Casal Fernández, Leonor Varela Lema, Alberto Ruano Raviña, Jasjit S. Ahluwalia , Iñaki Galán

      • Resumen

      págs. 1561-1569

      

    • Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology

      Mónica Maria Guillot Morales, Laura Visa, Elena Brozos Vázquez, Jaime Feliu Batlle, Parham Khosravi Shahi, Berta Laquente Sáez, Borja López de San Vicente Hernández, Teresa Macarulla Mercadé, Regina Gironés Sarrió

      • Resumen

      págs. 1570-1583

      

    • Current approaches in glioblastoma multiforme immunotherapy

      Marjan Aghajani, Nazila Jalilzadeh, Amirhossein Yari, Peyman Tabnak, Amirhossein Mardi, Hossein Saeedi, Leili Aghebati Maleki, Behzad Baradaran, Ali Aghebati Maleki

      • Resumen

      págs. 1584-1612

      

  • RESEARCH ARTICLE

    • Surgical margins and prognosis of borderline and malignant phyllodes tumors

      Jialin Su, Fangxuan Li, Jie Zhang, Lu Gan, Shanling Liu, Gang Tu

      • Resumen

      págs. 1613-1622

      

    • On the need of in vivo verifcations as quality control for intraoperative electron radiotherapy in breast cancer

      Carla Cases, Gabriela Oses González, Antonio Herreros, Jordi Tarrats Rosell, Sara Moreno López, Meritxell Mollà Armadà

      • Resumen

      págs. 1623-1629

      

    • Doxorubicin‑induced chemoresistance in Duke’s type B colon adenocarcinoma cell line is aggravated in the presence of TGF‑β2 through non‑apoptotic cell death

      Sruthi Sritharan, Nageswaran Sivalingam

      • Resumen

      págs. 1630-1638

      

    • Criteria and indicators to evaluate quality of care in genitourinary tumour boards

      Javier Puente Vázquez, Daniel Castellano-Gauna, Ignacio Durán, Paula Gratal, María Teresa Pardo, Vicente Guillem Porta, F. Algaba, Óscar Buisán Rueda, Juan José Fernández Ávila, A. Gómez-Iturriaga, Mariano José Parada Blázquez, Daniel Adolfo Pérez Fentes, Gemma Sancho, Juan Antonio Vallejo Casas

      • Resumen

      págs. 1639-1646

      

    • Multidisciplinary approach for locally advanced non‑small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

      Aylen Vanessa Ospina Serrano, Mariano Provencio Pulla, Sergio Bolufer Nadal, José Luis Campo Cañaveral de la Cruz, V. Calvo de Juan, José Luis González Larriba, Florentino Hernando Trancho, José Ramón Jarabo Sarceda, Ivan Macia Vidueira, Bartomeu Massuti Sureda, E. Nadal, Antonio Álvarez Kindelan, Edel del Barco Morillo, Reyes Bernabé-Caro, Joaquim Bosch Barrera, Joaquín Casal Rubio, Javier de Castro Carpeño, Ángel Cilleruelo Ramos, Manuel Cobo Dols, Manuel Dómine Gómez, Santiago Figueroa Almánzar, María Rosario García Campelo, Amelia Insa Mollá, Unai Jiménez Maestre, R. Lopez Castro, Margarita Majem, Elisabeth Martínez Téllez, Alex Martínez, David Sanchez Lorente

      • Resumen

      págs. 1647-1663

      

    • Real‑world evaluation of first‑line treatment of extensive‑stage small‑cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis

      Hanxiao Chen, Yanhui He, Jun Zhao, Minglei Zhuo, Xiangjuan Ma, Jian Fang, Jie Liu, Yu Yang, Yong Fang, Liping Wang

      • Resumen

      págs. 1664-1673

      

    • Is there a preferred platinum and fuoropyrimidine regimen for advanced HER2‑negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

      Aránzazu Arias Martínez, Eva Martínez de Castro, Javier Gallego Plazas, Virginia Arrazubi Arrula, Ana Custodio, Ana Fernández Montes, Marc Díez Garcia, Raquel Hernández San Gil, María Luisa Limón, Juana María Cano Cano, María del Rosario Vidal Tocino, Ismael Macías Declara, Laura Visa, M. Martin Richard, Tamara Saurí Nadal, Cinta Hierro Carbó, Mireia Gil Raga, Paula Cerda, Elia Martínez Moreno, Nieves Martínez Lago, Antonio José Mérida García, Lucía Gómez González, Francisco Javier García Navalón, Maribel Ruiz Martín, Gema Marín Zafra, Flora López López, Ana Belen Rupérez Blanco, Alejo Fernández Muinelo, P. Jiménez Fonseca, Alberto Carmona Bayonas, Felipe Alvarez Manceñido

      • Resumen

      págs. 1674-1686

      

    • Comparison of the eficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastases

      Manyi Xu, Yanhua Wang, Yue Hao, Keda Shao, Zhengbo Song

      • Resumen

      págs. 1687-1695

      

    • MET overexpression correlated with prognosis of EGFR‑mutant treatment‑naïve advanced lung adenocarcinoma: a real‑world retrospective study

      Na Wang, Junhua Wu, Bo Huang, Jun Fan, Xiu Nie, Yuan Zhang, Yili Zhu, Ying Wu, Ruiguang Zhang

      • Resumen

      págs. 1696-1707

      

    • Insight into the signifcance of Foxp3+tumor‑infltrating lymphocytes in squamous cell lung cancer

      Kazu Shiomi, Shoko Hayashi, Dai Sonoda, Yasuto Kondo, Raito Maruyama, Masashi Mikubo, Yukitoshi Satoh, Masaaki Ichinoe, Yoshiki Murakumo, Ai Ushiwata, Koji Eshima, Ryo Nagashio

      • Resumen

      págs. 1708-1715

      

    • A signature of circulating miRNAs predicts the prognosis and therapeutic outcome of taxane/platinum regimen in advanced ovarian carcinoma patients

      Ranita Pal, Trisha Choudhury, Madhurima Ghosh, Vilas Deorao Nasare, Manisha Vernakar, Partha Nath

      • Resumen

      págs. 1716-1724

      

    • Eficacy and safety of a combination treatment of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta‑analysis

      Ying Wang, Yalan Sun, Fang Lu, Xianghong Zhao, Bangshun He, Zhenlin Nie, Feng Zhu

      • Resumen

      págs. 1725-1737

      

    • Impact of platinum‑based chemotherapy on the tumor mutational burden and immune microenvironment in non‑small cell lung cancer with postoperative recurrence

      Jianghua Wu, Wei Sun, Luning Mao, Xiaozheng Huang, Dongmei Lin, Yanhui Zhang, Tingting Ding

      • Resumen

      págs. 1738-1747

      

    • Elderly patients with hormone receptor‑positive HER2‑negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

      Helena Pla Juher, Gemma Viñas, Roser Fort Culillas, Sonia del Barco Berrón, Eudald Felip, Mireia Margelí Vila, Beatriz Cirauqui Cirauqui, Vanessa Quiroga, Anna M. Esteve, Verónica Obadia, Sonia Pernas Simon, Agostina Stradella, Juan Miguel Gil Gil, Sabela Recalde, Nuria Sabaté, Eduard Fort Casamartina, Clara Lezcano Rubio

      • Resumen

      págs. 1748-1758

      

    • Bladder‑sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle‑invasive bladder cancer: a real‑world study

      Cheng Luo, Shuhang Luo, Wumier Wusimanjiang, Zongren Wang, Junxing Chen, Bin Huang, Ping Liu, Nan Deng, Kaihui Wu, Bin Wang, Xuejin Zhu, Dan Yuan, Hao Lin, Abai Xu, Peng Xu

      • Resumen

      págs. 1759-1767

      

    • Molecular profle in endometrial carcinoma: can we predict the lymph node status? A systematic review and meta‑analysis

      Ana Luzarraga Aznar, Vicente Bebia Conesa, Natalia Rodriguez Gomez Hidalgo, Marta Miguez Medina, María Asunción Pérez Benavente, Antonio Gil Moreno, Silvia Cabrera Díaz, Carlos López Gil, Eva Colas Ortega

      • Resumen

      págs. 1768-1778

      

    • The S‑REAL study: Spanish real‑world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

      Ana Gomez Rueda, María Pilar Garrido López, Álvaro Taus-García, Rosa Álvarez Álvarez, Reyes Bernabé-Caro, Luis Enrique Chara Velarde, Marta López-Brea, Laia Vilà Martínez, Maria Ángeles Sala Gonzalez, Anabel del Barrio Díaz Aldagalán, Beatriz Esteban Herrera, R. Lopez Castro, Ruth Álvarez Cabellos, Marta Doménech Catalán, Sandra Falagán Martínez, A. L. Moreno Vega, Carlos Aguado de la Rosa, Andrés Barba, María Teresa Delgado Ureña, Dolores Isla Casado, Lorena Bellido, José Luis Fírvida Pérez, Óscar Juan Vidal, Bartomeu Massuti Sureda, Xabier Mielgo, Ana Laura Ortega Granados, Silvia Catot Tort, Manuel Dómine Gómez, Corina Escoin Pérez, Francisco García Navalón, Ignacio Gil-Bazo, Silvia Muñoz Hita, Delvys Rodríguez Abreu, Rosa María Villatoro Rodlán, Guillermo Alonso-Jaúdenes Curbera, Luis León Mateos, Airam Padilla Álvarez, Alfredo Paredes Lario, José Miguel Sánchez Torres

      • Resumen

      págs. 1779-1789

      

    • SBRT‑SG‑01: final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases

      C. Rubio Rodríguez, Ovidio Hernando Requejo, Mercedes López, Emilio Sánchez Saugar, Jeannette Josefina Valero Albarrán, Angel Montero, Raquel Ciérvide Jurío, Beatriz Álvarez, Mariola García Aranda, Mónica Nuñez Baez, S. Flamarique, Maider Campo, Maitane Rodríguez, X. Chen Zhao, Rosa Alonso, Pedro Fernández Letón, D. Zucca Aparicio, Miguel Ángel de la Casa de Julián, Daniel Martínez, Fernando Mañeru Cámara, Juan García, Paz Garcia de Acilu, Leyre Alonso Iracheta, Jaime Martí, Fernando Arias de la Vega

      • Resumen

      págs. 1790-1797

      

  • BRIEF RESEARCH ARTICLE

    • Cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage I seminoma treated with a risk‑adapted strategy:: a Spanish single‑centre retrospective analysis

      Jose C. Tapia Tapia, Javier Gavira, Georgia Anguera Palacios, Sofia Sanchez del Río, Alejandra Romano, Freya Bosma Ainaud, Alejandra Molina Pérez, Judit Sanz Beltran, Cristina Martin Lorente, Pablo Maroto Rey, Fernando Algaba

      • Resumen

      págs. 1798-1803

      

  • CORRECTION

    • Correction: Surgical margins and prognosis of borderline and malignant phyllodes tumors

      Jialin Su, Fangxuan Li, Jie Zhang, Lu Gan, Shanling Liu, Gang Tu

      págs. 1804-1805

      

  • EDITORIAL EXPRESSION OF CONCERN

    • Editorial Expression of Concern: miRNA signatures in childhood sarcomas and their clinical implications

      G. M. Viera, K.B. Salomao, G. R. de Sousa, M. Baroni, L. E. A. Delsin, J. A. Pezuk, M. S. Brassesco

      págs. 1806-1806